(0.02%) 5 518.25 points
(0.13%) 39 897 points
(0.06%) 19 762 points
(-0.02%) $81.61
(0.50%) $2.83
(-0.24%) $2 338.80
(0.14%) $29.57
(0.59%) $1 007.70
(0.12%) $0.933
(-0.05%) $10.53
(0.02%) $0.788
(-0.85%) $87.25
-1.90% $ 3.10
Live Chart Being Loaded With Signals
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK...
Stats | |
---|---|
Dzisiejszy wolumen | 351 793 |
Średni wolumen | 686 198 |
Kapitalizacja rynkowa | 78.51M |
EPS | $-1.260 ( Q1 | 2024-05-09 ) |
Następna data zysków | ( $-1.030 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.720 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00800 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-18 | Bunn Paul A. | Buy | 12 500 | Stock Option (right to buy) |
2024-06-18 | Bunn Paul A. | Buy | 8 333 | Common Stock |
2024-06-18 | Rowinsky Eric K | Buy | 12 500 | Stock Option (right to buy) |
2024-06-18 | Rowinsky Eric K | Buy | 8 333 | Common Stock |
2024-06-18 | Kapur Anil | Buy | 12 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
49.14 |
Last 100 transactions |
Buy: 638 383 | Sell: 236 292 |
Wolumen Korelacja
Verastem Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Verastem Inc Korelacja - Waluta/Towar
Verastem Inc Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
FY | 2022 |
Przychody: | $2.60M |
Zysk brutto: | $2.48M (95.45 %) |
EPS: | $-4.58 |
FY | 2021 |
Przychody: | $2.05M |
Zysk brutto: | $2.05M (100.00 %) |
EPS: | $-0.464 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej